External beam radiotherapy (EBRT) is a cornerstone in cancer management. Radiation is lethal to cancer cells, but the exposure of neighbouring healthy tissues can lead to dose-limiting toxicity. The localized delivery of EBRT also limits its ability to treat disseminated disease.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Acknowledgements
The authors thank S. Bhattacharya, E. Looney, and Ruoyao Chen for contributions to understanding the next-generation landscape of RLTs.
Competing Interests
The authors are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies. The research for this specific article was funded by BCG's healthcare practice.
